FF
RCKT icon

FourThought Financial’s Rocket Pharmaceuticals RCKT Stock Holding History

FourThought Financial’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-695
Closed -$11K – 1537
2022
Q1 		$11K Hold
695
– – ﹤0.01% 1028
2021
Q4 		$15K Hold
695
– – ﹤0.01% 994
2021
Q3 		$20K Buy
695
+13
+2% +$473 ﹤0.01% 952
2021
Q2 		$30K Hold
682
– – ﹤0.01% 850
2021
Q1 		$30K Buy
682
+263
+63% +$14.4K ﹤0.01% 819
2020
Q4 		$22K Buy
+419
New +$15.3K ﹤0.01% 853

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FourThought Financial's RCKT Position: Q2 2022 in Review

FourThought Financial sold out of Rocket Pharmaceuticals (RCKT) in Q2 2022, closing a stake of 695 shares — an estimated $11K sold.

FourThought Financial first reported a position in RCKT in Q4 2020 and held it in 6 quarters. The position peaked at $30K in Q2 2021. 147 funds tracked by Wall St. Rank hold RCKT as of Q2 2022.

  • FourThought Financial reported no remaining Rocket Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • FourThought Financial sold 695 Rocket Pharmaceuticals shares in Q2 2022, an estimated $11K.
  • FourThought Financial first reported a position in Rocket Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • FourThought Financial's Rocket Pharmaceuticals position peaked at $30K in Q2 2021.
  • 147 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2022.

Based on FourThought Financial's 13F filing for Q2 2022, filed 12 Aug 2022.